FOLD · As filed with the SEC
Amicus Therapeutics cash flow statement, by fiscal year
The statement as Amicus Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Cash Flows · USD thousands
| USD thousands | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 |
|---|---|---|---|---|
| Operating activities | ||||
| Net loss | (27,110) | (56,106) | (151,584) | (236,568) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Amortization of debt discount and deferred financing | 2,570 | 2,262 | 2,616 | 2,634 |
| Depreciation and amortization | 7,460 | 8,547 | 7,873 | 5,342 |
| Stock-based compensation | 87,410 | 84,905 | 86,077 | 76,512 |
| Loss on extinguishment of debt | 0 | 0 | 13,933 | 0 |
| Non-cash changes in the fair value of contingent consideration payable | 0 | 0 | 2,583 | 1,078 |
| Foreign currency remeasurement loss | 3,586 | 16,234 | 19,613 | 6,121 |
| Non-cash deferred taxes | 0 | 0 | (4,939) | 9 |
| Asset impairment charges and other write-offs | (1,138) | 9,210 | 2,727 | 18,177 |
| Changes in operating assets and liabilities: | ||||
| Accounts receivable | (5,860) | (19,484) | (20,108) | (17,330) |
| Inventories | (111,483) | (73,652) | (44,614) | (5,343) |
| Prepaid expenses and other current assets | (1,382) | 13,961 | (8,062) | (6,194) |
| Accounts payable, accrued expenses, and other current liabilities | 82,777 | (16,520) | 49,195 | (6,377) |
| Other non-current assets and liabilities | (3,685) | (3,248) | (3,054) | (4,636) |
| Payment of contingent consideration | 0 | 0 | (21,347) | 0 |
| Net cash provided by (used in) operating activities | 33,145 | (33,891) | (69,091) | (166,575) |
| Investing activities | ||||
| Sale and redemption of marketable securities | 51,269 | 117,779 | 197,227 | 335,926 |
| Purchases of marketable securities | (94,405) | (114,786) | (91,723) | (243,255) |
| Capital expenditures | (3,296) | (3,553) | (7,440) | (3,766) |
| Proceeds from sale of assets | — | 0 | 0 | 3,411 |
| Net cash (used in) provided by investing activities | (46,432) | (560) | 98,064 | 92,316 |
| Financing activities | ||||
| Proceeds from issuance of common stock from equity financing and pre-funded warrants, net of issuance costs | — | — | — | 0 |
| Proceeds from the issuance of shares in connection with at-the-market offering, net of issuance costs | 0 | 19,566 | 63,108 | — |
| Proceeds from equity financing, net of issuance costs | 0 | 0 | 29,827 | — |
| Withholding taxes paid on vested restricted stock units | (18,323) | (22,025) | (17,920) | (11,490) |
| Proceeds from stock options exercised, net | 19,205 | 7,677 | 10,261 | 4,310 |
| Proceeds from warrants exercised, net | 0 | 0 | 12 | 0 |
| Payment of long-term debt | 0 | 0 | (408,043) | 0 |
| Proceeds from long-term debt, net of issuance costs | 0 | 0 | 387,360 | 0 |
| Payment of contingent consideration | 0 | 0 | (2,653) | 0 |
| Payment of finance leases | (272) | (97) | (275) | (283) |
| Net cash provided by financing activities | 610 | 5,121 | 61,677 | (7,463) |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 13,277 | (4,031) | 6,312 | (14,619) |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 600 | (33,361) | 96,962 | (96,341) |
| Cash, cash equivalents, and restricted cash at the beginning of the year | 216,716 | 250,077 | 153,115 | 249,456 |
| Cash, cash equivalents, and restricted cash at the end of the year | 217,316 | 216,716 | 250,077 | 153,115 |
| Supplemental disclosures of cash flow information | ||||
| Tenant improvements paid through lease incentive | — | — | 105 | 0 |
| Tenant improvements paid through lease incentive | 390 | 315 | — | — |
| Cash paid during the period for interest | 43,608 | 58,960 | 36,090 | 34,358 |
| Cashless exercise of warrants | 71 | — | — | — |
| Capital expenditures unpaid at the end of period | 73 | 103 | 868 | 1,141 |
| Cash paid for income taxes | 14,894 | 8,214 | 8,525 | 1,609 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.